Wiederherstellung und Aufrechterhaltung eines Sinusrhythmus bei Patienten mit Vorhofflimmern

Zusammenfassung

Die Therapie des Vorhofflimmerns, der häufigsten Herzrhythmusstörung im Erwachsenenalter, stellt zusammen mit der altersabhängigen steigenden Prävalenz in einer zunehmend alternden Gesellschaft eine wachsende Herausforderung dar. Aktuelle medikamentöse Therapieansätze zur Wiederherstellung und Erhaltung eines Sinusrhythmus werden durch die begrenzte Effektivität, Tolerabilität und Sicherheit der bisher eingesetzten Antiarrhythmika eingeschränkt. Ein primäres Ziel ist somit die Entwicklung von wirkungsvollen Medikamenten mit möglichst geringem Nebenwirkungsprofil Die folgende Übersicht beschreibt neue vielversprechende medikamentöse Therapieansätze, die die bislang bestehenden Probleme und Grenzen der Antiarrhtmika, zumindest partiell, überwinden.

Summary

Atrial fibrillation is the most frequent cardiac arrthythmia in adults and its prevalence is increasing with age. Therefore, the importance of an adequate therapy is an increasing challenge, in particular considering the demographic shift towards an aging population. Current antiarrhythmic drug therapies for the conversion of atrial fibrillation and the maintenance of sinus rhythm are limited by efficacy, tolerance and safety of the currently available agents. Therefore, a primary goal is to develop effective antiarrhythmic drugs with as little as possible side effects. The following review describes new promising drug therapy approaches to atrial fibrillation that may overcome some of the limitations of current therapies.

Vorhofflimmern - Antiarrhythmika - neue Therapieansätze - Ionenkanäle - Vorhofspezifische Wirkstoffe - Sinusrhythmus - Torsades de pointes

atrial fibrillation - antiarrhythmic drugs - new therapies - ion channels - atrial specific agents - sinus rhythm - torsades de pointes

Literatur

• 1 Stroke Prevention in Atrial Fibrillation Study. Final results.  Circulation. 1991;  84 (2) 527-539
• 2 Heart Rhythm, 2008, 29th Annual Scientific Sessions. San Francisco; 14. – 17. Mai 2008
• 3 Calo L, Bianconi L, Colivicchi F. et al . N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.  J Am Coll Cardiol. 2005;  45 (10) 1723-1728
• 4 Dale K M, White C M. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.  Ann Pharmacother. 2007;  41 (4) 599-605
• 5 Deedwania P C, Singh B N, Ellenbogen K. et al . Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.  Circulation. 1998;  98 (23) 2574-2579
• 6 Ehrlich J R, Biliczki P, Hohnloser S H, Nattel S. Atrial-selective approaches for the treatment of atrial fibrillation.  J Am Coll Cardiol. 2008;  51 (8) 787-792
• 7 Ehrlich J R, Hohnloser S H, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.  Eur Heart J. 2006;  27 (5) 512-518
• 8 Fauchier L, Pierre B, de Labriolle A. et al . Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.  J Am Coll Cardiol. 2008;  51 (8) 828-835
• 9 Fuster V, Ryden L E, Cannom D S. et al . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).  J Am Coll Cardiol. 2006;  48 (4) 854-906
• 10 Gautier P, Guillemare E, Djandjighian L. et al . In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects.  J Cardiovasc Pharmacol. 2004;  44 (2) 244-257
• 11 Gautier P, Serre M, Cosnier-Pucheu S. et al . In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.  J Cardiovasc Pharmacol. 2005;  45 (2) 125-135
• 12 Gerth A, Höss J, Näbauer M, Steinbeck G. Epidemiologie von Vorhofflimmern. In: Lewalter T, editor Rationale Arrhythmiebehandlung – Ein Paradigmenwechsel. Darmstadt; Steinkopff 2006: 13-22
• 13 Goette N. Neue Aspekte der medikamentösen antiarrhythmischen Therapie. In: Lewalter T, editor Rationale Arrhythmiebehandlung – Ein Paradigmenwechsel. Darmstadt; Steinkopff 2006: 23-9
• 14 Goldschlager N, Epstein A E, Naccarelli G V. et al . A practical guide for clinicians who treat patients with amiodarone: 2007.  Heart Rhythm. 2007;  4 (9) 1250-1259
• 15 Haverkamp W, Haverkamp F, Breithardt G. Medikamentenbedingte QT-Verlängerung und Torsade de pointes.  Deutsches Ärzteblatt. 2002;  99 (28 – 29) A1972-A1979
• 16 Healey J S, Baranchuk A, Crystal E. et al . Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.  J Am Coll Cardiol. 2005;  45 (11) 1832-1839
• 17 Hohnloser S H, Kuck K H, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.  Lancet. 2000;  356 (9244) 1789-1794
• 18 Humphries K H, Lee M, Sheldon R. et al . Statin use and recurrence of atrial fibrillation after successful cardioversion.  Am Heart J. 2007;  154 (5) 908-913
• 19 Kjolbye A L, Haugan K, Hennan J K, Petersen J S. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.  Basic Clin Pharmacol Toxicol. 2007;  101 (4) 215-230
• 20 Kowey P R, Aliot E M, Capucci A. et al . Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter. (Abstract).  Heart Rhythm. 2007;  4 S72
• 21 Lee K W, Everett T H, Rahmutula D. et al . Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure.  Circulation. 2006;  114 (16) 1703-1712
• 22 Lip G Y, Tse H F. Management of atrial fibrillation.  Lancet. 2007;  (9587) 370 604-618
• 23 Maggioni A P, Latini R, Carson P E. et al . Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).  Am Heart J. 2005;  149 (3) 548-557
• 24 Mathew J P, Fontes M L, Tudor I C. et al . A multicenter risk index for atrial fibrillation after cardiac surgery.  JAMA. 2004;  291 (14) 1720-1729
• 25 Morrow J P, Cannon C P, Reiffel J A. New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?.  Am Heart J. 2007;  154 (5) 824-829
• 26 Mozaffarian D. Fish oil and prevention of atrial fibrillation.  J Am Coll Cardiol. 2007;  50 (15) 1513-1514
• 27 Patti G, Chello M, Candura D. et al . Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.  Circulation. 2006;  114 (14) 1455-1461
• 28 Pedersen O D, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.  Circulation. 1999;  100 (4) 376-380
• 29 Rahme M M, Cotter B, Leistad E. et al . Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100 302 in experimental atrial flutter and fibrillation.  Circulation. 1999;  100 (19) 2010-2017
• 30 Roy D, Pratt C M, Torp-Pedersen C. et al . Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.  Circulation. 2008;  117 (12) 1518-1525
• 31 Roy D, Rowe B H, Stiell I G. et al . A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.  J Am Coll Cardiol. 2004;  44 (12) 2355-2361
• 32 Ruskin J N. The cardiac arrhythmia suppression trial (CAST).  N Engl J Med. 1989;  321 (6) 386-388
• 33 Sablayrolles S, Le Grand B. Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.  Curr Opin Investig Drugs. 2006;  7 (9) 842-849
• 34 Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.  Europace. 2008;  10 (6) 647-665
• 35 Singh B N, Aliot E. Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity?.  European Heart Journal Supplements. 2007;  9 (Supplement G) G17-G25
• 36 Singh B N, Singh S N, Reda D J. et al . Amiodarone versus sotalol for atrial fibrillation.  N Engl J Med. 2005;  352 (18) 1861-1872
• 37 Thrall G, Lip G Y, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation.  Chest. 2007;  132 (4) 1259-1264
• 38 Touboul P, Brugada J, Capucci A. et al . Dronedarone for prevention of atrial fibrillation: a dose-ranging study.  Eur Heart J. 2003;  24 (16) 1481-1487
• 39 Van Gelder I C, Hagens V E, Bosker H A. et al . A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.  N Engl J Med. 2002;  347 (23) 1834-1840
• 40 Vassallo P, Trohman R G. Prescribing amiodarone: an evidence-based review of clinical indications.  JAMA. 2007;  298 (11) 1312-1322
• 41 Vermes E, Tardif J C, Bourassa M G. et al . Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.  Circulation. 2003;  107 (23) 2926-2931
• 42 Schacky C von. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both?.  Curr Opin Clin Nutr Metab Care. 2008;  11 (2) 94-99
• 43 Waldo A L, Camm A J, deRuyter H. et al . Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.  Lancet. 1996;  348 (9019) 7-12
• 44 Wyse D G, Waldo A L, DiMarco J P. et al . A comparison of rate control and rhythm control in patients with atrial fibrillation.  N Engl J Med. 2002;  347 (23) 1825-1833
• 45 Yin Y, Dalal D, Liu Z. et al . Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.  Eur Heart J. 2006;  27 (15) 1841-1846